Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: dayonebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2025 | $25.00 | Overweight | Piper Sandler |
| 10/9/2024 | $32.00 → $33.00 | Buy | Needham |
| 8/1/2024 | $11.00 → $24.00 | Underperform → Buy | BofA Securities |
| 4/24/2024 | $30.00 → $33.00 | Buy | Needham |
| 4/25/2023 | $34.00 → $9.00 | Buy → Underperform | BofA Securities |
| 2/8/2023 | $40.00 | Overweight | CapitalOne |
| 2/3/2023 | Perform | Oppenheimer | |
| 12/15/2022 | $35.00 | Buy | H.C. Wainwright |
| 12/14/2022 | $40.00 | Buy | Needham |
| 12/5/2022 | $45.00 | Buy | Goldman |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
Fastest customizable press release news feed in the world
Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval data to also be disclosed for the first time BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will present new OJEMDA durability and clinical stability data from the registrational FIREFLY-1 study at the 30th Annual Meeting & Education Day of the Soc
Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-year FIREFLY-1 data to be released in oral presentation at Society for Neuro-Oncology on Nov. 23, 2025 Ended the third quarter with $451.6 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, November 4, 4:30 p.m. Eastern Time BRISBANE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targete
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2025. Live audio of the webcast will be accessible in the Events section of Day One's Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days following the event. About Da
OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter with $453.1 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, August 5, 4:30 p.m. ET BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its second quarter 2025 financial results and
BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the second quarter 2025. Live audio of the webcast will be accessible on Day One's Events on the Day One Media & Investors page. An archived version of the webcast will be available for replay on the News & Events section of the Day One Media & Investors p
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development (R&D). "We are thrilled to welcome Mike during this pivotal time at Day One. As an
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2025 financial results and highlighted recent corporate achievemen
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2024 financial results and highli
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2024. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & M
SCHEDULE 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
10-Q - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
SCHEDULE 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SCHEDULE 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
10-Q - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)
144 - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz
For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz
Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity
Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 217700, Application Classification: Type 1 - New Molecular Entity
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Piper Sandler initiated coverage of Day One Biopharmaceuticals with a rating of Overweight and set a new price target of $25.00
Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $32.00 previously
BofA Securities upgraded Day One Biopharmaceuticals from Underperform to Buy and set a new price target of $24.00 from $11.00 previously
Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $30.00 previously
BofA Securities downgraded Day One Biopharmaceuticals from Buy to Underperform and set a new price target of $9.00 from $34.00 previously
CapitalOne initiated coverage of Day One Biopharmaceuticals with a rating of Overweight and set a new price target of $40.00
Oppenheimer initiated coverage of Day One Biopharmaceuticals with a rating of Perform
H.C. Wainwright initiated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $35.00
Needham initiated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $40.00
Goldman initiated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $45.00
Live finance-specific insights
Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-year FIREFLY-1 data to be released in oral presentation at Society for Neuro-Oncology on Nov. 23, 2025 Ended the third quarter with $451.6 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, November 4, 4:30 p.m. Eastern Time BRISBANE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targete
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2025. Live audio of the webcast will be accessible in the Events section of Day One's Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days following the event. About Da
OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter with $453.1 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, August 5, 4:30 p.m. ET BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its second quarter 2025 financial results and
BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the second quarter 2025. Live audio of the webcast will be accessible on Day One's Events on the Day One Media & Investors page. An archived version of the webcast will be available for replay on the News & Events section of the Day One Media & Investors p
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2025 financial results and highlighted recent corporate achievemen
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2024 financial results and highli
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2024. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & M
Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its third quarter 2024 financial results and highlighted recent corporate achievements. "Our third quarter results demonstrate continued patient demand
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30
Live Leadership Updates
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development (R&D). "We are thrilled to welcome Mike during this pivotal time at Day One. As an
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology
BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors. "We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Their deep expertise and leadership in oncology will further strengthen our Board and will be a great asset as we prepare for the potential launch of ou
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncology where he led its global oncology franchise. Day One co-founder Julie Grant, who served as board chair since 2021, will continue to serve as a member of the board of directors. "Garry is an accompl
Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022 Upcoming CTOS Meeting to Highlight Single Agent Activity of Lead Drug Candidate, DAY101, in Spindle Cell Carcinoma Compassionate Use Case SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced financial results for the third quarter of 2021 and highlighted recent corporate achievements. "We continue to build momentum in our le
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced the appointment of Jaa Roberson as chief people officer. In her role, Ms. Roberson will oversee all aspects of Day One's human resources and talent acquisition efforts. "Day One is built on a foundation of talented employees who share a strong commitment and passion for developing innovative targeted therapies to improve the lives of children and people of all ages living with cancer," said Jeremy Bender, P
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the appointment of Scott Garland to the Company's board of directors. Mr. Garland is a 30-year veteran of the biopharmaceutical industry with deep commercial and executive leadership experience. "We are very pleased to welcome Scott to our board of directors at this important stage in Day One's evolution," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Having led the launch of multiple new m
This live feed shows all institutional transactions in real time.
SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13D/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)
SC 13D/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)